Zacks Investment Management Protagonist Therapeutics, Inc Transaction History

Zacks Investment Management

  • $8.87 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 15, 2023
BUY
$18.02 - $29.36 $3,892 - $6,341
216 Added 1.97%
11,168 $308,000
Q2 2023

Aug 14, 2023
SELL
$18.02 - $29.36 $16,380 - $26,688
-909 Reduced 7.66%
10,952 $302,000
Q1 2023

May 15, 2023
BUY
$10.78 - $25.38 $127,861 - $301,032
11,861 New
11,861 $272,000

Others Institutions Holding PTGX

# of Institutions
212
Shares Held
59.1M
Call Options Held
19K
Put Options Held
107K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Zacks Investment Management Portfolio

Follow Zacks Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Zacks Investment Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email